dc.contributor.author
Sabater, Ana
dc.contributor.author
Ciudad i Gómez, Carlos Julián
dc.contributor.author
Cendros, Marc
dc.contributor.author
Dobrokhotov, Denis
dc.contributor.author
Sabater i Tobella, Joan, 1934-
dc.date.issued
2020-06-15T15:34:07Z
dc.date.issued
2020-06-15T15:34:07Z
dc.date.issued
2019-05-29
dc.date.issued
2020-06-15T15:34:07Z
dc.identifier
https://hdl.handle.net/2445/165552
dc.description.abstract
We present g-Nomic, a pharmacogenetics interpretation software that analyzes globally a prescribed medication taking into account the personal background genetics, drug-drug interactions, lifestyle, nutritional supplements, inhibitors, inducers, and other risks to analyze primary or secondary metabolism pathways. G-Nomic provides a set of recommendations describing the suitability of a given combination of drugs for each patient according to their genes and polymedication. G-Nomic is updated monthly including data from the new drugs to be included, their known interactions, and the relevant pharmacokinetic biomarkers. For the interactions, the list is curated manually, only keeping those with clinical relevance. For each drug, their FDA and EMA drug labels are accessed, to check for relevant enzymes and transport proteins that influence its pharmacokinetics, and for their ability to induce or inhibit other enzymes, particularly the CYP-450 system. When this information is not available, a PubMed search is made to look for these characteristics. In addition, a distinction is made between drugs and prodrugs. A query on the g-Nomic software begins with entering the medication by either their common or commercial name. Non-pharmacological substances can be also added or selected under 'lifestyle habits'. The lifestyle list is dynamic, showing only the substances known to interact with the drugs that are currently selected, and includes herb compounds, such as St. John's wort, as well as proper lifestyle substances such as grapefruit or cigarette smoking. The software provides a list of the genes classified as primary biomarkers as candidates for genetic testing, and a list of the interactions that have been detected. If genetic information is available then, or is made available at a later point, these results can also be entered and the software returns pharmacogenetics recommendations regarding specific genotypes. g-Nomic takes all the above-mentioned parameters in an easy and user-friendly tool making prescription safer.
dc.format
application/pdf
dc.publisher
Dove Medical Press
dc.relation
Reproducció del document publicat a: https://doi.org/10.2147/PGPM.S203585
dc.relation
Pharmacogenomics and Personalized Medicine, 2019, vol. 12, p. 75-85
dc.relation
https://doi.org/10.2147/PGPM.S203585
dc.rights
cc-by-nc (c) Sabater, Ana et al., 2019
dc.rights
http://creativecommons.org/licenses/by-nc/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Fisiologia)
dc.subject
Farmacogenètica
dc.subject
Marcadors bioquímics
dc.subject
Pharmacogenetics
dc.subject
Biochemical markers
dc.subject
Computer software
dc.title
g-Nomic: a new pharmacogenetics interpretation software
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion